Sjõgren's syndrome, an autoimmune disorder in which immune cells attack and destroy the exocrine glands that produce tears and saliva, afflicts somewhere between 1 and 4 million people in the United States. This issue of Rheumatic Disease Clinics of North America examines the clinically important aspects of this disorder and features articles on the following topics: pathogenesis; hepatitis C involvement; measurement of disease activity; relationship to other autoimmune disorders; involvement of the respiratory tract; involvement of the nervous system; lymphoma and Sjõgren's syndrome; fatigue; optimizing dry mouth treatment; management of dry eye; issues in DMARD and biological therapy; and therapeutic potential for B-cell modulation.